Form D · Pharmaceuticals
Expanesthetics, Inc
Davis, X1 · CIK 0001716170
Offering snapshot reported Mar 4, 2024 · SEC filing
- Reported sold
- $372K Offering amount: $372K
- Investors reported
- 37 Form D · investor count
- Minimum accepted
- $5.1K Reported outside-investor minimum
- First sale
- Oct 9, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 4, 2024 | Initial | $372,300 | No comparison | 37 | SEC filing |
| Mar 4, 2024 | Initial | $234,260 | No comparison | 6 | SEC filing |
| Sep 8, 2023 | Initial | $356,400 | No comparison | 18 | SEC filing |
| Sep 8, 2023 | Initial | $282,338 | No comparison | 13 | SEC filing |
| Sep 8, 2023 | Initial | $20,496 | No comparison | 4 | SEC filing |
| Feb 9, 2023 | Initial | $227,700 | No comparison | 17 | SEC filing |
| Feb 9, 2023 | Initial | $554,233 | No comparison | 20 | SEC filing |
| Jan 7, 2022 | Amendment | $84,857 | $74,875vs Oct 13, 2021 | 1 | SEC filing |
| Jan 7, 2022 | Initial | $1,292,646 | No comparison | 33 | SEC filing |
| Oct 13, 2021 | Initial | $9,982 | No comparison | 1 | SEC filing |
| Aug 6, 2021 | Amendment | $823,108 | No comparison | Not reported | SEC filing |
| Jun 3, 2021 | Initial | $433,367 | No comparison | 23 | SEC filing |
| Jun 2, 2021 | Amendment | $342,640 | $232,838vs Oct 15, 2020 | 20 | SEC filing |
| Jun 2, 2021 | Amendment | $219,604 | -$69,874vs Feb 1, 2021 | 16 | SEC filing |
| Feb 1, 2021 | Amendment | $289,478 | $49,910vs Oct 15, 2020 | 15 | SEC filing |
| Oct 15, 2020 | Initial | $109,802 | No comparison | 6 | SEC filing |
| Oct 15, 2020 | Initial | $239,568 | No comparison | 14 | SEC filing |
| Sep 10, 2020 | Amendment | $708,125 | $0vs Apr 21, 2020 | 34 | SEC filing |
| Sep 10, 2020 | Initial | $260,897 | No comparison | 22 | SEC filing |
| Sep 10, 2020 | Amendment | $769,091 | $450,221vs Sep 23, 2019 | 28 | SEC filing |
| Apr 21, 2020 | Amendment | $708,125 | No comparison | 34 | SEC filing |
| Oct 31, 2019 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Sep 23, 2019 | Amendment | $318,870 | $212,625vs May 14, 2019 | 10 | SEC filing |
| May 14, 2019 | Initial | $106,245 | No comparison | 3 | SEC filing |
| Mar 5, 2019 | Initial | $445,140 | No comparison | 29 | SEC filing |
| Mar 5, 2019 | Amendment | $1,163,593 | $0vs Aug 14, 2018 | 57 | SEC filing |
| Mar 5, 2019 | Amendment | $1,393,561 | $791,911vs Jan 22, 2018 | 48 | SEC filing |
| Aug 14, 2018 | Initial | $1,163,593 | No comparison | 57 | SEC filing |
| Jan 22, 2018 | Initial | $601,650 | No comparison | 7 | SEC filing |
| Sep 11, 2017 | Initial | $2,926,888 | No comparison | 70 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-506601
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| n/a | None |
Source: Form D, filed Mar 4, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Shane Austin | Executive |
| Landon Ellis | Executive |
| Robert Erwin | Director |
| Richard Fowler | Director |
| Jenna Hansen | Director |
| Lon Hatamiya | Director |
| Mark Holman | Director, Executive |
| Claire Pomeroy | Director |
| Christopher Stone | Executive |
| Todd Strumwasser | Director |
| Brian Woodall | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1450 Drew Ave. Suite 100
Davis, X1, 95618
Davis, X1, 95618